



**Patient Cases - Plasma Cell Dyscrasia (PCD) - 3/27/2025
3/27/2025 12:00:00 PM - 3/27/2025 1:30:00 PM**

By texting in your attendance, you will be awarded the maximum number of CE credits. If you wish to claim less than the maximum CE credits, please contact MDAnderson-CPE@mdanderson.org

Target Audience:

Professions: Physician (MD or DO), Nurse - RN, Nurse - APRN

Learning Objectives:

- 1 Incorporate awareness among healthcare providers and implementing standardized screening protocols to identify cases.
- 2 Promote the use of advanced diagnostic techniques to improve accuracy and early detection of Plasma Cell Dyscrasia (PCD).

Accreditation:



In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this live activity will award 1.50 Nursing Contact Hour(s)

Commercial Support:

No commercial support has been received for this activity.

Disclosure of Financial Relationships:

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty & Planner Disclosure:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Behrang Amini, MD, PhD	Other Planning Committee Member	Independent Contractor (included contracted research)- ImpactBio Membership on Advisory Committees or Review Panels, Board Membership, etc.-Deciphera - 09/26/2024
Robert Z Orlowski, MD, PhD	Other Planning Committee Member	Grant or research support-Bristol-Myers Squibb Company Grant or research support-CARSgen Therapeutics Grant or research support-Exelixis (Relationship has ended) Grant or research support-Heidelberg Pharma Grant or research support-Janssen Biotech, Inc. Grant or research support-Sanofi Genzyme Grant or research support-Millennium Pharmaceuticals, Inc., The Takeda Oncology Company Grant or research support-Asylia Therapeutics (Relationship has ended) Advisor-AbbVie Inc. (Relationship has ended) Advisor-Adaptive Biotech (Relationship has ended) Advisor-Karyopharm Therapeutics (Relationship has ended) Advisor-Meridian Therapeutics Advisor-Monte Rosa Therapeutics (Relationship has ended) Advisor-Nanjing IASO Biotherapeutics Advisor-Neoleukin Corporation (Relationship has ended) Advisor-Oncopeptides AB (Relationship has ended) Advisor-Regeneron Pharmaceuticals, Inc. Advisor-Sporos Bioventures, Inc. Advisor-Millennium Pharmaceuticals, Inc., The Takeda Oncology Company Advisor-Asylia Therapeutics, Inc. (Relationship has ended) Advisor-BioTheryX (Relationship has ended) Advisor-Bristol-Myers Squibb Company Advisor-Pfizer Inc. - 05/01/2024
Andres E Quesada, MD	Activity Co-Director, Faculty	Nothing to disclose - 11/20/2024
Tiffany Richards, PhD, AN-BC, AOCNP	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.- Bristol-Myers Squibb Company Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc. Membership on Advisory Committees or Review Panels,

		Board Membership, etc.- GlaxoSmithKline Consulting Fee- Regeneron Pharmaceuticals, Inc. - 03/03/2025
Jing Ye, MD, MS	Activity Director	Advisor-Janssen Biotech, Inc. Consulting Fee-Pfizer Inc. Honoraria-Sanofi US (Relationship has ended) - 01/20/2025